General
Preferred name
LINCOMYCIN
Synonyms
U10149A ()
Lincomycin HCl ()
NSC 70731 ()
Lincomycin hydrochloride hydrate ()
LINCOMYCIN HYDROCHLORIDE ()
Lincomycin hydrochloride monohydrate ()
Lincomycin (hydrochloride monohydrate) ()
Lincomix ()
Lincomycin hydrochloride usp ()
Lincocin ()
Lincolnensin hydrochloride ()
Lincomycin (as hydrochloride) ()
Albiotic ()
NSC-757092 ()
Lincomycin hydrochloride anhdrous ()
Lincolnensin hydrochloride monohydrate ()
NSC-70731 ()
Lincolnensin ()
U-10149 ()
U-10,149 ()
Lincomycin ()
Lincomycin ()
P&D ID
PD013336
CAS
859-18-7
7179-49-9
154-21-2
17431-82-2
Tags
natural product
drug
available
Approved by
FDA
First approval
1964
Drug Status
approved
vet_approved
Drug indication
Antibacterial
Gram-positive bacterial infection
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS
Lincomycin is a lincosamide antibiotic that produced by Streptomyces lincolnensis. Lincomycin has been shown to be active in vitro against the following microorganisms: Aerobic gram-positive cocci: Streptococcus pyogenes and Viridans group streptococci; Aerobic gram-positive bacilli: Corynebacterium diphtheriae; Anaerobic gram-positive non-sporeforming bacilli: Propionibacterium acnes; Anaerobic gram-positive sporeforming bacilli: Clostridium tetani and Clostridium perfringens.
ROE
Urinary excretion after this dose ranges from 1.8 to 24.8 percent (mean: 3 percent). Biliary excretion is also an important route of excretion.
HALF-LIFE
The biological half-life after intramuscular or intravenous administration is 5.4 ± 1.0 hours. The serum half-life may be prolonged in patients with severe impairment of renal function. Half life may be extended up to 2-fold in patients with hepatic impairment.
DESCRIPTION
Lincomycin is a lincosamide antibacterial that has activity against Gram-positive and anaerobic bacteria . It was isolated from the actinomycete Streptomyces lincolnensis. Pathogenic species of bacteria that are sensitive to lincomycin include Streptococcus, Staphylococcus, and Mycoplasma.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
18
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine BioReference Compounds
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
Prestwick Chemical Library
Selleckchem Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
72
Molecular Weight
406.21
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
5
Rotatable Bonds
7
Ring Count
2
Aromatic Ring Count
0
cLogP
-0.86
TPSA
122.49
Fraction CSP3
0.94
Chiral centers
9.0
Largest ring
6.0
QED
0.37
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Microbiology&virology
Anti-infection
Target
50S ribosome
antibiotic
Bacterial
Antibiotics,Antibiotics for Mammalian Cell Culture
Indication
enteritis
MOA
bacterial 30S ribosomal subunit inhibitor
Therapeutic Class
Antibiotics
Source data
